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A Deadly Dimorph: What You Need to Know About Blastomyces spp. 
Introduction 
Maxx had just returned from spending a holiday weekend at a camp near Geraldton, 
Ontario when his owners noticed he just “wasn’t himself.” He began coughing and then “started 
licking his paws a lot.” When his paws began to bleed, that was enough for Maxx to be taken to 
the vet. He had symptoms of fever, swollen lymph nodes, high white blood cell counts, lesions 
over his entire body – “including inside his adorable ears” - swelling limbs and paws. These 
symptoms, along with a positive fungal spore test confirmed a diagnosis: Blastomycosis. Things 
progressed quickly, too quickly it seemed. Maxx was put on aggressive antifungal therapy. 
Shortly after his visits to the vet, his right eye became swollen, and Maxx returned to the vet, 
who confirmed that Blastomyces spp. was spreading to his eye. Even after three days of eye 
drops and aggressive oral drugs, his right eye became so cloudy and painful that it had to be 
surgically removed.  
Maxx’s story, adapted from the local daily newspaper in Thunder Bay, Ontario, is 
familiar among dog owners. Blastomycosis infection rates for dogs are ten times higher than 
humans; they are the second most common host of this deadly fungal pathogen. Working as a 
medical laboratory technologist and supervisor of the Mycology Department at Public Health 
Ontario Laboratories (PHOL) in Thunder Bay, Ontario, I see approximately 1800 human 
specimens requesting fungus culture testing yearly. Anywhere between 30 and 50 of those are 
typically new patients diagnosed with Blastomyces dermatitidis or Blastomyces gilchristii 
(Blastomyces spp.). Since I began working at PHOL in June of 2000, I have taken an interest in 
the Mycology Department and enjoy working with fungal cultures. My interest peaked in 2005 
when the Thunder Bay District Health Unit (TBDHU) requested us to spike soil samples with 
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cultures of Blastomyces spp. for anonymous trial testing at another laboratory that performed the 
Polymerase Chain Reaction (PCR) test. The TBDHU wanted a method to test soil samples in  
and around the Thunder Bay area. Fewer than three years later, the investigation was 
“unearthed.” Of the 45 soil samples collected, 12 tested positive for the fungus (Dunn, 2008). It 
was then that my passion for the research of this and other deadly human fungal pathogens 
began. 
This literature review is a summarization of the progression of research from the 
discovery of the species Blastomyces dermatitidis through to our current understanding of the 
disease blastomycosis and the organisms involved in this potentially deadly infection, 
Blastomyces spp. For more than a century, many dedicated researchers have added to the current 
knowledge of this pathogen. Building from this knowledge, four significant areas are 
contributing to our present understanding of Blastomyces spp. These areas involve the diagnosis, 
prognosis, treatment and prevention of blastomycosis. Each of these areas link to the four 
sections of this literature review: The tasks of the laboratory, the infection in the host, the 
monitoring by the physician and veterinarian, and the health unit’s public awareness. From these 
sections, the review will conclude with a discussion of where the future lies with this deadly Risk 
Group 3 (RG3) (Public Health Agency of Canada, 2015, Chapter 2.3.1.3) fungal pathogen. 
Definitions 
The following words used in the text are defined in terms of how they are used in the 
field. They are provided here for quick reference and convenience. 
 Antibody – produced by the host as part of a defence mechanism when infected with a 
pathogen. 
 Antigen – a foreign body (e.g. a pathogen) to the host that can cause antibody production. 
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 Dimorphic – having two forms. 
 Direct specimen – an unaltered sample of body fluid or tissue from the host. 
 Filamentous (mould) form – composed of lengthy thread-like structures. 
 Hematogenous – distributed via the bloodstream. 
 Immunocompetent – no known compromising health issues that may affect the immune 
system. 
 Immunocompromised – having other existing health issues that affect the natural immune 
system. 
 Macrophages – the first line of defence in the immune system. 
 Media – a substance used for the growth of organisms in the laboratory. 
 Sensitivity – how well a test can find positives. 
 Specificity – how well a test can eliminate false positives. 
 Spores – the form an organism produces for protection against adverse environmental 
conditions. 
 T-lymphocytes – blood cells that are alerted by macrophages (other blood cells) to fight 
infection. 
 Virulence – a pathogen’s ability to infect its host. 
 Yeast form – round or oval, usually budding. 
The Laboratory 
The knowledge, procedures and protocols developed in microbiological laboratories over 
the past 200 years has played a significant role in diagnosing human pathogenic fungal 
infections. This section will discuss the laboratory’s contribution throughout the organism’s 
discovery, investigation and methods of identification. 
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The Discovery 
Blastomyces dermatitidis (B. dermatitidis) was first isolated in 1894, when the English-
American dermatologist, Thomas Casper Gilchrist (Figure 1.), attempted to classify a previously 
unknown organism found in a skin lesion initially diagnosed as Scrofuloderma (an infection 
caused by tuberculous bacilli). Initially, Gilchrist (1896) thought it was a protozoan, but upon 
further examination of subsequent specimens, decided on fungal: 
In reporting the case before the American Dermatological Society I expressed the opinion 
that these bodies in all probability would be found to belong to plant rather than to animal 
life, and further examination appeared to verify the conclusion that they might be classed 
as Blastomycetes. (p. 271) 
 
Since then, many scientists have investigated this 
organism for its properties relating to disease. Meece et al. 
(2011) noted the genus B.dermatitidis had two genetically 
distinct forms and so put them in two different Groups, 
speculating that each may influence virulence and 
pathogenicity. Brown et al. (2013) have shown through 
genetic analysis that these two Groups were, in fact, two 
distinct species: “Our analyses provide evidence for the 
existence of two genetically distinct monophyletic clades 
within B. dermatitidis, which we use to describe a novel 
cryptic species, Blastomyces gilchristii” (p. 2) in honour of 
Gilchrist, the 1894 discoverer. Before genetic analysis, a 
characteristically similar disease was noted from Africa 
but found to be more closely related to the genus Emmonsia (McTaggart, Brown, & Richardson, 
2016). This pathogen was examined one year later by Dukik et al. (2017) and found to be 
Figure 1. The English-American 
dermatologist, Thomas Casper 
Gilchrist (1862-1927) (Borroni, 
Cananzi, & Vassallo, 2004) . 
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phylogenetically closer to the genus Blastomyces and so gave it the name Blastomyces percurses 
(B. percursus). B. percursus however, differs in appearance microscopically in both its yeast and 
mould forms whereas B. dermatitidis and Blastomyces gilchristii (B. gilchristii) are 
indistinguishable. Further examination of Blastomyces spp. led to a key physical characteristic, 
placing them in a group with other potentially fatal fungal pathogens known colloquially among 
mycologists as the “dimorphs.” 
Dimorphism 
Fungi are normally seen as one of two main physical forms, yeast and filamentous. The 
yeasts are round or oval and budding, and usually appear creamy on laboratory media. The 
filamentous or mould, taken from the Norse “mowlde” for fuzzy (Mycoses Study Group 
Education and Research Consortium, 2018) form consists of string-like hyphae with various 
types of spores or conidia and usually appear fuzzy on laboratory media. Gilchrist (1896) 
recognized these two forms, thus giving the newly isolated fungus a descriptive name: 
Blastomycetes, which are noted as “a class of pathogenic imperfect fungi that typically grow like 
yeasts by budding but sometimes form a mycelium and conidia on artificial media” (Merriam-
Webster, 2018). Most fungi exist as one form or the other. However, some species exhibit both 
forms depending on environmental factors. This phenomenon, as seen in the genus Blastomyces 
and a few other human pathogenic fungi, is termed dimorphism (two bodies or forms). Although 
Blastomyces spp. had been influenced to exhibit these two forms using special media alone 
(Kane, 1984), Levine and Ordal (1946) determined an optimal temperature of each form. Thus 
the term thermal dimorphism was later fashioned by Nickerson and Edwards (1949).  
As deadly a fungus as Blastomyces spp. can be, they are of high curiosity and study in the 
mycology laboratory for their diagnostic forms and dimorphic nature (Scherr & Weaver, 1953). 
A DEADLY DIMORPH  7 
 
The function of each of these forms was described by Marty et al. (2015), as the yeast form 
facilitating immune evasion and the mould form generating transmissible spores, promoting 
survival in the environment and sexual reproduction. Baumgardner (2016) explains why the 
mould to yeast transition facilitates the fungus’ ability to infect so successfully: “The resultant 
yeast cell is too large to be ingested by polymorphonuclear neutrophils (PMNs), unlike the 
smaller infectious conidia particles (spores)” (p. 61). Gauthier (2017) explains precisely that “the 
morphologic switch to yeast is associated with the upregulation of specific virulence factors that 
promote adhesion to host tissues, growth in and lysis of macrophages, blunt proper cytokine 
responses, and impair cell-mediated immunity” (p. 5). The dimorphic nature of Blastomyces spp. 
allows it to successfully infect its mammalian host. Researchers questioned where the organism 
resides prior to inoculation, ultimately discovering its ecological niche to be the soil. 
Identification in Soil 
As early as 1902, the diagnosis was made microscopically on a direct specimen, and was 
later speculated by Brayton (1902) that the organism originated in soil “Those affected … are 
people in contact with the soil and its products; they are laborers, carpenters, etc” (p. 315). 
Gilchrist (year) appropriately named the disease “blastomycetic dermatitis” as it was initially 
diagnosed from an infection of the skin. However, Schwarz and Baum (1951) noted in a case 
study that most patients with skin lesions from Blastomyces spp., also showed a positive disease 
in the lungs. They speculated that “this lends strong weight to the belief that the primary lesion in 
blastomycosis is in the lung and that almost all skin lesions are the result of hematogenous 
spread from this primary lesion” (Schwarz & Baum, 1951, p. 1022).  
This gave credence to the speculation of a course of infection from soil to host. In the 
organism’s mould phase at the lower environmental temperature, the spores produced are easily 
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dispersed if disturbed, creating the ability to be inhaled into the host lung causing disease (Klein 
et al., 1986). It was not proven as a soil organism until Denton and DiSalvo (1964), by “the 
intravenous inoculation of soil suspensions in the tail vein of mice…recovered [Blastomyces 
spp.] from 10 of 356 samples collected in an endemic area at Augusta, GA” (p. 716). In 2006, 
Burgess, Schwan, and Volk (2006) developed a specific assay via PCR, to test soil samples for 
the detection of Blastomyces spp. Use of this method led to the investigation of positive soil 
samples and speculation that “the ability of B. dermatitidis to survive and grow in organic 
carbon-poor, high ammonia microenvironments may be important to the competitive success of 
this fungus” (Baumgardner, 2009, p. 745). How then did the organism travel from soil to host? 
Identification in the Host 
Proving soil origin of Blastomyces spp., it was then speculated that the disturbance of the 
soil, whether by the influence of the weather (such as by temperature variations and windy 
conditions) or host involvement (physical manipulation of the earth), or both, liberates the spores 
into the air making them available for inhalation via the respiratory tract (Baumgardner, 
Bernhard, & Egan, 2015, pp. 30–31). This was supported by the fact that dogs, especially ones 
that love to dig in the soil, have been known to be up to 14 times more likely to be infected than 
humans, especially in endemic areas and near waterways (Baumgardner, Paretsky, Baeseman, & 
Schreiber, 2011). 
Due to the pathogenicity of this potentially fatal fungus, the desire was to have a 
diagnostic test indicating positive exposure to Blastomyces spp. Researchers attempted to 
develop a test for blastomycosis, creating Blastomycin, an intradermal skin test (not unlike the 
tuberculin skin test for TB), but it was later found to be unreliable (Lancaster & Sprouse, 1976) 
and consequently there is no skin test currently in use. Immunological testing was then pursued 
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to identify antibodies produced by the host in response to the infection. Several methods were 
created including complement fixation, immunodiffusion and enzyme immunoassay but were 
found to have unacceptable sensitivity, specificity or both (Abuodeh, Chester, & Scalarone, 
2004; Bradsher & Bariola, 2011). A better test proved to be the antigen itself: “By detecting 
antigens produced by the fungal organism instead of antibodies produced by the infected 
individual, a more rapid diagnosis may be made” (Shurley, Legendre, & Scalarone, 2005, p. 
141). Physicians occasionally use antigen detection for blastomycosis. However, for 
identification and follow-up treatment, urine antigen testing is popular among veterinarians 
because of the ease of obtaining these samples in dogs (Foy, Trepanier, Kirsch, & Wheat, 2014).  
Currently, the standard laboratory analysis for diagnosis in humans is growth in culture 
with confirmation by PCR, or conversion from the mould phase back to the characteristic yeast. 
When specimens are received in the laboratory, it can take more than two weeks for the 
organism to grow. Therefore a direct smear is performed on the sample for a more rapid report. 
Blastomyces spp. in a specimen presents in the diagnostic yeast form, thus with the expertise of a 
trained mycologist or pathologist, a preliminary report can inform the physician directly. With 
this initial result, along with travel history and typical signs and symptoms of the disease, it is 
possible for the physician to diagnose and begin treatment without undue delay. 
The Host 
Following inoculation of Blastomyces spp. in the host, the resulting infection produces a 
variety of signs and symptoms. However, it is the immune status of the patient and other 
influences that affect how the disease invades  the body. This section outlines the development of 
infection of Blastomyces spp. in the mammalian host, from the time the organism enters the body 
to the final, possibly fatal, outcome of the disease. 
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Inoculation  
As the name dermatitidis suggests, the skin was assumed to be the initial site of entry; it 
was then discovered that it was more likely the lungs via inhalation of spores from the soil. Since 
then, research and investigations have alluded to alternate ports of entry. There are five 
documented modes of infection described as: “(1) inhalation, (2) accidental inoculation, (3) dog 
bites (a form of inoculation), (4) conjugal, and (5) intrauterine transmission” (DiSalvo, 1992, p. 
76). Farber, Leahy, and Meadows (1968) investigated a case of sexual transmission; however, 
this was a rare case and circumstances were unique. Panciera, Troy, and Purswell (2014) 
conducted a study on an infected pregnant dog and demonstrated the unlikeliness of 
transplacental infection. Currently, the most common port of entry for infection is through 
inhalation of spores, with consequent dissemination to the other organs including skin, kidney, 
bone, eyes and brain.  
Further investigation from other interested researchers shows the intrigue behind this 
mysterious fungus. Varani, Baumgardner, Czuprynski, and Paretsky (2009) “failed to 
demonstrate asymptomatic nasal carriage of B. dermatitidis in a moderate sized sample of dogs 
from a highly endemic area” (p. 781), but suggests that the test they used may have been 
insensitive. The current consensus among researchers and physicians was first presented by 
Schwarz and Baum (1951) who revealed evidence “that cutaneous blastomycosis is most 
frequently secondary to a primary pulmonary infection” (p. 1026). In detailing specific case 
studies, both Emer and Spear (2009) and Kumar and Kumar (2015) proposed that a direct 
inoculum of the skin had disseminated to the lungs, the opposite to what is suggested by previous 
research. Mason, Cortes, Cook, Maize, and Thiers (2008) discussed the difficulties 
understanding the disease, arguing that the determination whether a dermal infection begins as a 
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direct inoculation or is secondary to a subclinical lung infection can be difficult without proper 
specimens, reliable laboratory testing and chest radiographs. Regardless of the portal of entry, 
once Blastomyces spp. enters and invades the host, the indicators of infection in the body can be 
ambiguous. 
Progression 
Following inoculation, the progression of Blastomyces spp. ranges from asymptomatic to 
the development of a painful and debilitating illness requiring aggressive medical treatment. The 
usual pathogenesis of the organism begins after the spores enter the respiratory tract, well 
described by Klein, Aizenstein, and Hogan (1997): “Upon transformation into the pathogenic 
yeast phase, B. dermatitidis multiplies within the lung and disseminates via the bloodstream and 
lymphatics to cause disease in the skin, bone, genitourinary tract, and brain” (p. 1505). 
Regardless of how it enters and where it ends up inside the body, the organs it ultimately chooses 
to infect result in varied signs and symptoms of the disease. 
The following three descriptions relay just how destructive and painful this potentially 
fatal fungal pathogen can be to its host. First, Brayton (1902) quite descriptively illustrates the 
symptoms of ulcers caused by blastomycetic dermatitis:  
The symptoms are heat, redness, swelling and pain—a gnawing, burning and persistent 
pain, intensified at night, preventing sleep, leading to the use of opiates, and only relieved 
by the destruction of the invaded margins with caustic, or the actual cautery, or by the 
knife. (p. 314) 
 
Second, Kurtz and Sharpnack (1969) described a case history of the dissemination of 
Blastomyces spp. to the central nervous system (CNS): “Blastomycotic meningoencephalitis in a 
dog was characterized by granulomas, which occurred most frequently in the gray matter of the 
cerebrum and the granular layer of the cerebellum” (p. 376). Third, a description by Abuodeh et 
al. (2004) conveyed the seriousness of the infection: “[Blastomyces spp] can produce severe 
A DEADLY DIMORPH  12 
 
disease ranging from a severe tuberculosis-like infection to a more fatal disseminative form that 
can involve multiple organ systems such as the bone, skin, and central nervous system” (p. 143). 
It is evident that this organism is quite invasive. Consequently, almost all specimen sources, 
from easy to obtain sputa or urine to the more invasive brain or lung tissue, are accepted for 
fungus culture in the laboratory. As in many cases of infection, however, it is the host's natural 
defence mechanism that can determine the individual’s outcome of the disease. 
Host Immunity    
Most fungal pathogens opportunistically infect an immunocompromised host, however 
few, such as Blastomyces spp. and other dimorphs can infect a healthy (immunocompetent) one. 
The characteristics of dimorphic fungi are significant factors in the ability of the organism to 
cause infection. Datta and Hamad (2015) explain that the cell wall of fungi “not only serves as a 
structural barrier, but also protects against complement-mediated damage and osmotic lysis” (p. 
738).  Evidenced by Sugar and Picard (1991), the mould phase of Blastomyces spp. does not 
have the ability to cause disease and the organism must convert to the yeast phase for 
pathogenicity to occur. After studying the unique 
ability of this type of fungus, Medoff, Painter, and 
Kobayashi (1987) detailed the stages of transition 
when converting from mould to yeast forms, the 
first of which is triggered by the change in 
temperature to 37 °C, when the organism enters the 
body of the mammalian host.  Once inside the host 
the thick capsule of the yeast (Figure 2.) form, “is 
very difficult for phagocytes to ingest and kill [and] 
Figure 2. Blastomyces dermatitidis, 
showing the thick capsule of the yeast 
form (Rodriguez, 2018). 
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PMN’s, which handle inhaled conidia better than macrophages, are relatively ineffective … thus 
humoral immune responses do not play a significant role in host defense against B. dermatitidis” 
(Saccente & Woods, 2010, p. 369).  
Chang et al. (2000) claim that “humans infected with the dimorphic fungus Blastomyces 
dermatitidis develop strong T-lymphocyte responses” (p. 502). Therefore, the hosts with 
compromised immune systems may have a more difficult prognosis. In 2008, the United States’ 
Food and Drug Administration (FDA) issued a warning to immunocompromised individuals, 
listing B. dermatitidis as one of the organisms that may cause a severe and possibly fatal 
infection (FDA, 2018). Researchers continue to analyze the capability of Blastomyces spp. to 
invade so prolifically and efficiently. More recently, Gauthier (2017) highlighted how “the 
morphologic switch to yeast is associated with the upregulation of specific virulence factors that 
promote adhesion to host tissues, growth in and lysis of macrophages” (p. 5), giving the 
organism the ability to survive and thrive, resulting in a possibly fatal prognosis for the host. 
Prognosis 
Considering the many varied factors that are involved in infection, blastomycosis has a 
vague prognosis. With an indefinite incubation period of 21-106 days with a median of 43 days 
(Ministry of Health and Long-Term Care Government of Ontario, 2018) the likelihood of 
survival depends on many factors, especially the timeliness of diagnosis. It has been speculated 
that some infections “spontaneously” recover (Recht, Philips, Eckman, & Sarosi, 1979; Sarosi, 
Davies, & Phillips, 1986) while others cause a swift and debilitating death, with 
“immunocompromised hosts [having a] higher rate of ICU admission, development of [Acute 
Respiratory Distress Syndrome] ARDS and mortality” (Prueksaritanond et al., 2016, p. 1).  
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Following the discovery of the second distinct species of Blastomyces, there was 
speculation of pathogenic differences in virulence between the two organisms: B. dermatitidis 
and B. gilchristii (McTaggart et al., 2016). Brömel and Sykes (2005) found that the prognosis of 
the disease in some areas had worsened, suggesting “this may be related to geographic variations 
in strain virulence” (p. 237). More recently, Dalcin, Rothstein, Spinato, Escott, and Kus (2016) 
demonstrated in a case study, that B. gilchristii was responsible for a fatal infection, resulting in 
ARDS and causing death. However, the patient had a history of drug abuse and diabetes and was 
therefore considered immunocompromised, weakening their ability to fight the infection. If there 
are differences in strain virulence that result in a more predictable prognosis, it would have a 
significant and valuable influence on diagnosis, aiding the physician’s ability to treat the disease. 
The following section will detail some of the challenges faced by the physician when presented 
with an infected patient. 
The Physician and Veterinarian 
When a patient becomes infected with Blastomyces spp. and first presents to their 
physician, the clinical appearance along with the physician’s familiarity with blastomycosis will 
determine the diagnosis, treatment and final prognosis of the disease. In this section, the 
development of the disease is described through the eyes of the treating physician or 
veterinarian, from the initial visit through to a cure or termination of life. 
Presentation  
Some of the factors that influence the status of the patient at presentation are age and 
species of the host (the majority being dogs and humans), underlying health (immune status), the 
pathway and foci of infection and how long they have had symptoms. The age of the patient, 
however, should not rule out treatment; from very young children to mature adults, the disease 
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has been known to strike all age groups, as well as all genders and ethnicities (Crampton et al., 
2002; Fanella, Skinner, Trepman, & Embil, 2011; Saccente & Woods, 2010). Dogs, especially 
ones of the hunting and sporting breeds, are ten times more likely than humans to become 
infected by Blastomyces spp. (Armstrong et al., 1987; Pfaller & Diekema, 2010). Whether the 
host has a healthy immune system at the time of infection or not, the degree of pulmonary 
infiltration and dissemination to other areas of the body can be slight to severe, even expediting 
death (Chu, Feudtner, Heydon, Walsh, & Zaoutis, 2006; Lemos, Baliga, & Guo, 2001; Meyer, 
McManus, & Maki, 1993).  
While Gilchrist first diagnosed the disease as a skin infection, Brayton (1902), to assist 
other dermatologists, gave a descriptive account of a typical cutaneous infection (Figure 3.): 
The edges of these ragged and irregular ulcers are in a constant state of inflammation, 
extending perhaps from one-fourth to one-half an inch into the skin not yet breaking 
down. … Therefore the occurrence of multiple acneoid pustules in close proximity to 
each other occurring in unusual localities, unsymmetrically distributed and followed by 
necrosis and punctiform excavated ulcers, should call attention to the probability of 
blastomycosis. (p. 314-315) 
 
Presently, the patient 
typically first appears with 
unresolved pneumonia and 
a travel history to an 
endemic area, 
optimistically before 
dissemination to other 
organs. Physicians in 
endemic areas will 
consistently order 
Figure 3. Cutaneous blastomycosis (Chima-Okereke, 2015). 
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tuberculosis and fungus culture concurrently as blastomycosis and tuberculosis are similar in 
their presentation.  
Diagnosis 
Local physicians from endemic areas are familiar with the varied symptoms of 
blastomycosis and its similarity to other infections; however in non-endemic areas, if the 
patient’s travel history is not considered, it may take longer for diagnosis, which can prove fatal 
(Brown et al., 2018; Chu et al., 2006; Pfaff, Agger, & Volk, 2014). Therefore, it is best to rule 
out Blastomyces spp. in endemic areas if the patient is not responding to conventional 
antimicrobial therapy (Sutcliffe, 2017). Turning to canine infections, Brömel and Sykes (2005) 
give an account of what signs the veterinarian might expect for diagnosis:   
Clinical signs range from nonspecific (lethargy, weakness, anorexia, and weight loss) to 
more specific signs including cough, increased respiratory rate, lameness, or reluctance to 
walk. … Other clinical signs include localized soft tissue or bony swellings, blindness, 
seizures or other neurological signs, hemoptysis, hematemesis, melena, polyuria, 
polydipsia, and lumbar pain.... Common findings on physical examination are fever, 
peripheral lymphadenopathy, dyspnea or tachypnea … increased breath or lung sounds, 
and subcutaneous abscesses, or ulcerative draining lesions of the skin (e.g., muzzle, 
digits, body wall). (p. 234) 
 
Although it is not ideal for the animal to be suffering, if the disease has progressed to the point of 
dissemination to the skin, “cutaneous involvement by blastomycosis helps the clinicians to reach 
the correct diagnosis” (Lemos, Guo, & Baliga, 2000, p. 201). In cases where organs are severely 
compromised, surgery is performed along with antimicrobial therapy as in the decision to 
remove Maxx’s right eye.  
With its many modes of infection, and the multitude of organs it is capable of infecting, 
the difficulty the veterinarian or physician has in diagnosing blastomycosis can be daunting. 
Malignancy, other fungal pathogens, and especially pneumonia and tuberculosis have similar 
disease spectra, increasing the chance of misdiagnosis (Fanella et al., 2011; Lemos et al., 2000; 
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Saccente & Woods, 2010). Even in endemic areas, trying to rule out blastomycosis may be 
challenging for the physician when fungus cultures come back negative, due to the difficulty in 
obtaining a suitable specimen. (e.g. some patients have a difficult time producing a productive 
sputum sample). Lyou, Longoria, and Davoudi (2017), presented a case to illustrate this:  
A 48-year-old immunocompetent male presented with a subacute history of generalized 
fatigue, and an acute presentation of severe neck pain, headache, and gait instability [the] 
patient underwent extensive diagnostic workup including repeat cerebral spinal fluid 
examinations, serology, and brain biopsies which were non-diagnostic. Computed 
tomography (CT) chest was performed, which was notable for mild mediastinal and 
bilateral hilar lymphadenopathy. Flexible bronchoscopy with endobronchial ultrasound 
and transbronchial needle aspiration of the mediastinal lymph nodes confirmed the 
presence of lymphocytes and rare multinucleated giant cells. Ultimately, a 
mediastinoscopy and lymph node resection revealed broad-based budding yeast, favoring 
blastomycosis against a background of extensive necrotizing granulomas. (p. 1) 
 
For the veterinarian, urine is the most convenient sample to obtain, however, “diagnosis is best 
made through cytological identification on aspirates, biopsy, or bronchoalveolar lavage” (Lavely 
& Lipsitz, 2005, p. 216). For more difficult diagnoses in areas such as the CNS, where 
specimens can be difficult to obtain, a magnetic resonance imaging (MRI) may be considered 
(Bariola et al., 2010).  Nevertheless, of the many possible tests from specimens such as tissues, 
abscess fluids, sputa and urine, the “visualization of characteristic yeast forms or growth of the 
fungus in culture is necessary to diagnose blastomycosis definitively” (Saccente & Woods, 2010, 
p. 372). Typically, treatment does not begin unless blastomycosis is confirmed due to the 
aggressive nature and sometimes severe side effects of the anti-fungal drugs necessary to fight 
this infection. 
Treatment 
Blastomycosis “is almost invariably fatal without treatment” (Harasen & Randall, 1986, 
p. 1). Prior to antifungal drugs and before the disease was known to infect the lungs, it was 
common to debride the affected area and use iodides empirically as antibiotics were not effective 
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(Schwarz & Baum, 1951). Brayton (1902) vividly describes how blastomycetic dermatitis was 
treated in the early 1900’s: 
The knife, the hot iron, the application of carbolic acid followed by the concentrated acid 
nitrate of mercury, gives immediate relief, or at least as soon as the pain of the burning 
has been subdued by appropriate dressings ... with the further growth of the organism on 
one side or the other of the primary lesion, the intolerable pain again begins and the 
patient is willing to submit to a repetition of the destructive process, even begging to have 
the affected member amputated. (p. 314) 
 
Currently, of all the antifungal agents, Amphotericin B and many of the azoles are commonly 
effective in eradicating Blastomyces spp. Factors such as cost, effectiveness, drug-drug 
interactions and tolerability all play a role in the choice of treatment (Lavely & Lipsitz, 2005; 
Pappas et al., 1997; Saccente & Woods, 2010; Tyler, DeVier, Carpenter, Carr, & Trabue, 2013; 
Wiebe & Karriker, 2005), but in itself, Amphotericin B remains “the ‘gold standard’ by which all 
subsequent antifungals were compared because of its broad spectrum of activity against diverse 
fungi and the ability to cure otherwise recalcitrant life-threatening fungal infections” (Hector, 
2005, p. 42).  
Often, the challenge for the physician as well as the veterinarian is not the decision of 
“which drug to use, but rather, how much drug to use and for how long” (Hector, 2005, p. 247). 
In the canine community, “Itraconazole is the treatment of choice for blastomycosis in dogs 
because it produces fewer adverse effects, it is easier to administer, and its cost is similar to that 
of Amphotericin B treatment” (Legendre et al., 1996, p. 371). As it was with Maxx, the dog 
mentioned in the Introduction, “a combination of topical and systemic therapy is indicated in 
dogs with ocular blastomycosis” (Brömel & Sykes, 2005, p. 237). For humans, according to the 
Ministry of Health and Long Term Care (MOHLTC, 2018), most of those infected “will require 
treatment ...[and this] is indicated for all patients with progressive pulmonary or extrapulmonary 
diseases as well as those patients who are immunocompromised” (para. 18). Overall, if 
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diagnosed early, treated promptly, and with the cooperation of the patient, or dog owner, 
faithfully taking the prescribed medication, a good recovery is expected (Bariola et al., 2010; 
Meyer et al., 1993; Seitz, Adjemian, Steiner, & Prevots, 2015). 
Prognosis  
In a study done by Pappas et al. (1997) it was found that for a successful prognosis, the 
median length of time for antifungal therapy was eight months, with a range of 2 to 24 months. It 
was noted by Brömel and Sykes (2005) that “the success of treatment depends on the tissues 
involved, the degree of dissemination, the condition of the patient and the treatment regimen” 
(pp. 236-237). Bradsher and Bariola (2011) implore physicians that “careful follow-up for 
several years is mandatory in patients with acute pneumonia who do not receive antifungal 
therapy to ensure that there is no recrudescence of infection” (p. 344). A patient’s lack of 
symptoms may indicate that the infection enters a subclinical, asymptomatic or dormant stage 
and is not eradicated (Light et al., 2008). The immunocompetence of the host and the strength of 
the organism’s virulence (as suggested between the two species of Blastomyces) may be a factor 
in the reason for the suggestion of spontaneous recovery and other differential diagnoses (Lemos 
et al., 2001).  
Antifungal therapy is typically necessary to eradicate fungal pathogens, especially severe 
pulmonary and chronic skin infections. However, they come with a price. Patients must be 
carefully monitored while on antifungal drugs as commonly there are minor side effects 
including nausea, vomiting and diarrhea, but severe adverse effects can occur (i.e. liver toxicity 
and blood disorders) (Kukanich, 2008; Saccente & Woods, 2010). By only losing his right eye, 
Maxx was lucky as “most dogs with brain involvement will die, but aggressive treatment with 
Amphotericin B, Fluconazole, or Voriconazole may occasionally be effective” (Gaunt & Taylor, 
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2009, p. 255). In most clinical cases, even if the physician chooses the right drug, dose and 
length of treatment, they “still rely on the host’s immune response to ultimately clear any 
residual fungal burden” (Hector, 2005, pp. 240–241). The physician is faced with the fact that 
blastomycosis, not unlike other endemic fungal infections, at 90 days after diagnosis, has a 
mortality rate of 9.5% (Baddley et al., 2011). With such a deadly and invasive pathogen that is 
successfully treated if diagnosed early, awareness and prevention are justifiably warranted. The 
next section discusses the health unit’s challenge to educate the community about this deadly 
dimorph through public awareness, protection and prevention. 
The Health Unit 
The health unit’s (HU’s) primary role in the Ontario health system is to promote the well-
being of individuals in their districts. This can be accomplished through education programs and 
the awareness of strategies for protection from disease. When a disease is deemed “reportable,” 
the diagnosing physician must inform the HU for investigation and tracking purposes. The HU’s 
responsibility increases when a disease outbreak occurs; however it is preferred, through 
awareness and protection measures, that the spread of disease is prevented. The TBDHU is one 
of 36 Public Health Units in Ontario. The following section summarizes how blastomycosis has 
increased in awareness, influenced research, and will direct future studies, especially in the 
district of Thunder Bay, where blastomycosis cases are on the rise. 
Awareness 
Reportable disease of an RG3 organism. In Canada, B. dermatitidis is designated as an 
RG3 organism (Public Health Agency of Canada, 2011). This designation means it is a pathogen 
that is “likely to cause serious disease in a human or animal … effective treatment and 
preventive measures are usually available and the risk of spread of disease … is low for the 
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public” (Public Health Agency of Canada, 2015, Section 2.3.1.3). In Ontario, in 1989, B. 
dermatitidis was removed from the reportable list of organisms that require mandatory reporting 
to the local HU. Researchers and physicians, knowing the severity of the disease, were frustrated 
by the difficulties in tracking and investigating the organism. There have been repeated requests 
that blastomycosis cases become reportable once again (Brown et al., 2018; DiSalvo, 1992; 
Morris et al., 2006). These concerns were finally heard; as of May 1, 2018, Blastomyces spp. 
(both B. dermatitidis and B. gilchristii), have been designated reportable and blastomycosis was 
named a disease of public health significance in Ontario (MOHLTC, 2018). This designation 
will allow local health units to monitor the number of cases officially and potentially track where 
the fungus is most prevalent.  
Incidence. In some endemic areas of the United States, where blastomycosis remained 
reportable, records were reviewed to determine why there was generally a ten times higher risk 
for dogs to contract the disease over humans; it was noted that the dog’s desire to “sniff the 
ground” may be the reason for the higher number of canine cases (Harasen & Randall, 1986; 
Pfaller & Diekema, 2010). Neighbouring Northern Ontario, “in highly endemic Northern 
Wisconsin, USA, per-capita dog cases of blastomycosis occur at a rate 14-fold higher than that 
of humans” (Baumgardner et al., 2011, p. 49). In the United States, MacDonald, Langley, 
Gerkin, Torok, and MacCormack (2006) studied incidence rates in states where the disease 
remained reportable and found the rates to be 1.3-1.4 cases per 100,000 people. However, in 
hyperendemic areas, it climaxed at 41.9 cases per 100,000 people and is on the rise, likely 
influenced by environmental conditions. Even though the disease had not been reportable in 
Ontario, researchers have been estimating the prevalence of blastomycosis, but it is difficult to 
know where areas of increased incidence are occurring. Crampton et al. (2002) estimated “the 
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incidence rate for the Kenora district [in Northern Ontario], as 7.11 cases per 100,000 
population” (p. 1311). However, Morris et al. (2006) state that the true incidence is likely more 
than was predicted, and will increase when physicians and the community are more aware of the 
disease. The question remains; since blastomycosis is now reportable, will increased awareness 
of the disease be effective in reducing the number of cases in Ontario through prevention 
strategies? One Sault Ste Marie, Ontario, veterinarian, Dr. Poitras, does not think so, as he feels 
it cannot be eliminated from the soil in the environment (Ougler, 2017). Baddley et al. (2011) 
argue, however, that “knowledge of areas of increased incidence may improve diagnostic or 
prevention measures in older adults at risk for endemic mycoses, including those receiving 
immunosuppressive medications or with new environmental exposures” (p. 1668). By making 
the disease reportable, and thus increasing knowledge and awareness, the health unit will have a 
better chance at improving the healthcare of their residents through the education of protection 
and prevention procedures.  
Protection 
Avoidance prevention. One of the reasons blastomycosis was no longer considered a 
reportable disease in Ontario was that it was deemed not transmissible from person to person or 
even animal to person (unless bitten or by direct inoculation) (Schwarz & Baum, 1951). The 
search for how it becomes infective revealed Blastomyces spp. to be a soil organism, able to 
survive relative drought and high ammonia levels, inhabiting sandy soils, and along waterways 
with periods of intermittent moisture (Baumgardner, 2009, 2015; Baumgardner et al., 2011; 
McTaggart et al., 2016). Due to the severity of the disease once infected, and the toxicity of 
antifungal drug use, Burgess et al. (2006) felt PCR testing might best be used to confirm positive 
soil samples in endemic areas but still maintains the best practice is to use prevention measures 
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to avoid contracting the disease. Many attempts have been made to investigate environmental 
temperature and seasonal variations related to presentation, the type of infection (localized 
versus disseminated) and the prognosis of Blastomyces spp. in humans (Baumgardner, 2015; 
Baumgardner et al., 2011; Light et al., 2008) with only equivocal results. In his latest study of 
environmental exposure of the disease, Baumgardner et al. (2015) concludes that his research 
“illustrates the complexities involved in acquisition of this disease, likely a combination of 
environmental and temporal factors, host susceptibility and opportunity for exposure to the 
ecological niche of the involved fungus” (p. 31). For this reason, it is not surprising that the 
MOHLTC (2018) made the statement: “Decontamination of sites of exposure is not possible, and 
soil testing is not reliable [thus] early diagnosis and treatment of disease are therefore important 
control strategies” (p. 5). As a dedicated researcher of pathogenic fungi (including Blastomyces 
spp.) and someone who is interested in promoting prevention strategies, Baumgardner (2016), 
outlines general household routine measures to prevent accumulation of any mould indoors, from 
maintaining below 60% relative humidity to installing proper HVAC systems, in hopes of 
educating the community.  
Immunity. Many dedicated researchers are working hard to create a vaccine against 
Blastomyces spp. (Chang et al., 2000; Datta & Hamad, 2015; Scorzoni et al., 2017). Vaccines 
were considered a good option for blastomycosis, as it affects immunocompetent hosts – those 
with the ability to respond to vaccines – thus making them valuable (Spellberg, 2011). However, 
Spellberg (2011) outlines three barriers to the effectiveness of vaccines:  
First, vaccination would target the general population living in endemic areas and would 
require prolonged—or lifelong—immunity to be maintained.... A second barrier … is 
that, although the number of invasive infections per year caused by the endemic mycoses 
is quite large, these infections occur only in limited geographical areas, and [third,] the 
number of patients who develop significant sequelae from infection represents a small 
fraction of the total infected population. (p. 5) 
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Deepe, Wüthrich, and Klein (2005) added that the “lack of epidemiological data regarding 
incidence and prevalence of infection” is another barrier to the development of vaccines (p. 381). 
Due to the severity of fungal pathogens and the difficulty in diagnosis and treatment of 
blastomycosis, it is hoped through education and awareness that the clinical development of an 
efficient vaccine will be possible (Spellberg, 2011). Reaching out to the community for 
assistance in tracking this deadly disease will not only increase awareness through education, and 
promote the necessary precautionary measures, but will additionally assist in obtaining the data 
needed for researchers to identify endemic areas. 
Prevention 
 Epidemiology. At the beginning of the 20th century, Brayton (1902) astutely suspected 
that the disease was contracted from the soil by observing a higher number of infections in 
occupations that worked in these areas, but did not pursue this as a possibility. Schwarz and 
Baum (1951) suggested the acquisition of the disease came from animals as they produced 
evidence of “the failure to demonstrate transmission from man to man” (p. 1021). In the 
following decade, Denton and DiSalvo (1964), discovered: “that B. dermatitidis is a self-
sufficient saprophyte, capable of surviving and thriving in nature, and that it infects man only 
rarely by accident” (p. 716). Increasing awareness developed as endemic areas grew in the 
Northwestern Ontario area (Kane, Righter, Krajden, & Lester, 1983). A prospective case series 
by Nicolle, Rotstein, Bourgault, St-Germain, and Garber (1998) revealed a misleadingly high 
provincial incidence of blastomycosis in Manitoba as “the large unexposed population in 
southern Ontario decrease[d] the Ontario provincial incidence” (p. 351), thereby skewing the 
results. As the awareness grew, the desire and importance of epidemiological studies became 
realized; not just for knowledge of the ecological niche of the organism but for surveillance of 
A DEADLY DIMORPH  25 
 
the area and for the sake of prevention and public health awareness within and outside of the 
endemic areas (Benedict, Thompson, Deresinski, & Chiller, 2015; Burgess et al., 2006; 
Crampton et al., 2002; DiSalvo, 1992; MOHLTC, 2018).  
Studies that rely on retrospective data can limit the availability of information, thus 
restricting the ability to uncover specific locations of Blastomyces spp. in the soil (Baumgardner 
et al., 2011; Litvinjenko & Lunny, 2017; Pfaff et al., 2014). There is a need to design studies 
going forward to create survey information regarding travel history (humans) or soil contact 
information (dogs) and even species identifications and local weather conditions so risk factors 
can be determined (Chen, Legendre, Bass, Mays, & Odoi, 2008; Reed, Meece, Archer, & 
Peterson, 2008). Due to the natural inclination of dogs and their attraction to the typical niche of 
Blastomyces spp., they represent an excellent sentinel to create an epidemiological map. 
Baumgardner et al. (2015) noted that “dogs have long been considered harbingers of human 
blastomycosis, and in this area, there have been a mixed human and dog outbreak, same-
household cases over time, and similar geographic distributions of human and dog cases” (p. 30). 
Randhawa et al. (2013) suggested the “applications of PCR assays for rapid detection of B. 
dermatitidis in clinical and soil samples is highly promising for more rewarding future 
epidemiologic studies” (p. 190-191) and would also be useful in the confirmation and 
identification between the two Blastomyces spp. in endemic areas.  
Communication. As research progresses, the success in educating the community lies in 
the hands of the HU and knowledge mobilization techniques. There is a desire to communicate 
current information about this potentially fatal pathogen to the public that needs to know, and the 
physicians that need to treat infected patients (Baumgardner et al., 2015). Effective 
communication of well-researched information can “bridge the gap” between researchers and the 
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public, including physicians, veterinarians and health inspectors, and assist in putting the 
information into active use. Currently, the MOHLTC (2018) recommends that “public health 
units may consider periodic education reminders to health care providers ahead of the peak 
occurrence of blastomycosis in October-
December” (p. 5). However, if there were 
constant reminders in physician and 
veterinarian offices, such as posters or 
pamphlets, and the completion of surveys 
from affected people and their pets (Figure 
4.), it can not only increase awareness but 
also assist researchers, the medical 
community and health inspectors in their 
fight against this deadly dimorph.  
Conclusion 
Maxx was a lucky dog. His owners made sure he had the care he needed to survive. The 
veterinarian bills, which exceeded $4000, were subsidized by a caring friend telling their story 
on social media and a “gofundme” page. Without this help, the owner’s upcoming wedding was 
going to be put on hold. Maxx is currently on the road to recovery with another six months of vet 
visits and medication. It is still unknown where he had contracted the fungus; Blastomyces spp. 
typically has a three-week incubation period and the symptoms began within days of him 
returning home from a camping trip. Other than walks in the dog park, Maxx stays at his home. 
If Maxx did not live in Thunder Bay where veterinarians are cognizant of the symptoms of 
blastomycosis and thus sent the spores for testing, Maxx might not have survived. 
Figure 4. Panophthalmitis (inflammation of 
all layers of the eye) of a dog infected with 
ocular blastomycosis (Gaunt & Taylor, 
2009). 
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Blastomyces spp. are not the only dimorphic fungi that can be fatal in otherwise healthy 
hosts, particularly when they disseminate to other organs. Histoplasmosis and 
Coccidioidomycosis are also among the few known deadly dimorphic fungal infections. Even 
though dimorphic fungi can be lethal if untreated, infections are rare, which is a disadvantage 
when it comes to research funding for vaccines, advanced testing protocols and antifungal 
treatments. The onus lies in the hands of health units to identify areas of potential infection, and 
to mobilize the valuable researched information to the public for awareness and prevention. 
The best way to minimize the impact of this rare but often fatal pathogen is for everyone 
to work together. The laboratory, especially in endemic areas, should be well trained to identify 
the pathogen in the initial microscopic examination, to give the fastest turn-around time in 
reporting the disease to the physician. The patient, if aware of the condition and their possible 
exposure, can alert the examining physician with characteristic symptoms and travel history. The 
physician and veterinarians should be well educated on the latest research regarding diagnosis 
and treatment, especially in or near endemic areas. Finally, the health unit has the responsibility 
to mobilize the latest researched information to all parties, raising awareness. All four roles can 
work together in unearthing the high-risk areas of infection so that a continually updated 
epidemiological map can be created for the ongoing monitoring of the endemic regions of this 
fungus.  
As dogs are such great harbingers of this infection, it could be of benefit to use them as a 
guide to address the many unanswered questions about the epidemiology of Blastomyces spp., 
the main one being: Where is this organism found? In Ontario, Blastomyces is once again a 
reportable pathogen for humans, for both microscopic and culture results. This is a step in the 
right direction, but to get even more precise and current information, it is necessary to utilize the 
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data from canine cases. With the cooperation of dog owners, veterinarians can send specimens to 
the laboratory for diagnosis. The laboratory would alert the health unit of positive cases which 
can then immediately deliver detailed surveys to the dog owner and collect valuable evidence 
(e.g. home location or recent travel history before the first signs of illness). This information can 
track not only possible locations of infection but the virulence of the organism. An increase in 
canine case numbers can alert the health unit, physicians and the public and may predict or even 
prevent future outbreaks. Cultures collected by the laboratory with detailed survey information 
can be invaluable to researchers in future investigations and bring awareness to all parties 
concerned. Currently, it is not until a case like Maxx’s is detailed on social media that the 
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